IP Library Granted Patent US 9,359,625
Granted Patent B2
US 9,359,625 · App. 14/836,339 · Granted Jun 7, 2016

Chemical engineering processes and apparatus for the synthesis of compounds

Inventors: Robert Winnicki (Vancouver, CA); Marc Donsky (Vancouver, CA)
Assignee: Full Spectrum Laboratories Limited
C12P17/06A61K31/352C12M21/18C12M41/30C12Y121/03007C12Y121/03008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,359,625
App. No.
14/836,339
Granted
Jun 7, 2016
Kind
B2
Abstract

The present invention provides methods for producing cannabinoids and cannabinoid analogs as well as a system for producing these compounds. The inventive method is directed to contacting a compound according to Formula I or Formula II with a cannabinoid synthase. Also described is a system for producing cannabinoids and cannabinoid analogs by contacting a THCA synthase with a cannabinoid precursor and modifying at least one property of the reaction mixture to influence the quantity formed of a first cannabinoid relative to the quantity formed of a second cannabinoid.

Claims (31)

1. An in vitro method for producing

(a) tetrahydrocannabinolic acid (THCA) and cannabichromenic acid (CBCA) in different ratios, or

(b) cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA) in different ratios comprising the steps of:

reacting cannabigerolic acid (CBGA) with a cannabinoid synthase in a reaction mixture; selecting the pH of the reaction mixture in a range between about 4.0 and about 8.0 to produce

(i) tetrahydrocannabinolic acid (THCA) and cannabichromenic acid (CBCA) when the cannabinoid synthase is tetrahydrocannabinolic acid synthase (THCA synthase), or

(ii) cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA) when the cannabinoid synthase is cannabidiolic acid synthase (CBDA synthase), and

recovering the THCA and CBCA or CBDA and CBCA so produced.

2. The method of claim 1 , wherein the cannabinoid synthase is tetrahydrocannabinolic acid synthase (THCA synthase).

3. The method of claim 2 , wherein the cannabinoid synthase is immobilized on a solid support.

4. The method of claim 1 , wherein the cannabinoid synthase is a recombinant cannabinoid synthase, and the method further comprises producing the recombinant cannabinoid synthase.

5. The method of claim 4 , wherein the step of producing recombinant THCA synthase comprises overexpressing the THCA synthase.

6. The method of claim 5 , wherein the THCA synthase is expressed in yeast or in Escherichia coli.

7. The method of claim 1 , wherein the reaction mixture comprises a solvent, which is one or more of dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), iso-propoyl alcohol and cyclodextrin, and wherein the amount of the solvent in the reaction mixture is between 5% and 30% (w/v).

8. An ex vivo method for producing the products tetrahydrocannabinolic acid (THCA) and cannabichromenic acid (CBCA) in different ratios comprising the steps of:

reacting cannabigerolic acid (CBGA) with tetrahydrocannabinolic acid synthase (THCA synthase) in a reaction mixture;

modifying the pH of the reaction mixture in a range from about 4.0 and about 8.0 to produce tetrahydrocannabinolic acid (THCA) and cannabichromenic acid (CBCA) in different ratios; and

recovering the THCA and CBCA so produced.

9. The method of claim 8 , wherein the THCA synthase is immobilized on a solid support.

10. The method of claim 8 , wherein the THCA synthase is a recombinant THCA synthase, and the method further comprises producing recombinant THCA synthase.

11. The method of claim 10 , wherein the step of producing recombinant THCA synthase in large scale comprises overexpressing the THCA synthase.

12. The method of claim 11 , wherein the THCA synthase is expressed in yeast or in Escherichia coli.

13. The method of claim 8 , wherein the reaction mixture comprises a solvent, which is one or more of dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), iso-propoyl alcohol and cyclodextrin, and wherein the amount of the solvent in the reaction mixture is between 5% and 30% (w/v).

14. An ex vivo method for producing the products cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA) in different ratios comprising the steps of:

reacting cannabigerolic acid (CBGA) with cannabidiolic acid synthase (CBDA synthase) in a reaction mixture;

modifying the pH of the reaction mixture in a range between about 4.0 and about 8.0 to produce cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA) in different ratios; and

recovering the CBDA and CBCA so produced.

15. The method of claim 14 , wherein the CBDA synthase is immobilized on a solid support.

16. The method of claim 14 , wherein the CBDA synthase is a recombinant CBDA synthase, and the method further comprises producing recombinant CBDA synthase.

17. The method of claim 16 , wherein the step of producing recombinant CBDA synthase comprises overexpressing the CBDA synthase.

18. The method of claim 17 , wherein the CBDA synthase is expressed in yeast or in Escherichia coli.

19. The method of claim 14 , wherein the reaction mixture comprises a solvent, which is one or more of dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), iso-propoyl alcohol and cyclodextrin, and wherein the amount of the solvent in the reaction mixture is between 5% and 30% (w/v).

Assignments (7)
SECURITY INTEREST Recorded Nov 23, 2021
From: TEEWINOT TECHNOLOGIES LIMITED
To: TUATARA CAPITAL FUND I, L.P.; TUATARA CAPITAL PARALLEL FUND I, L.P.
Reel/Frame 058194/0448 →
SECURITY INTEREST Recorded Nov 23, 2021
From: TEEWINOT LIFE SCIENCES CORPORATION; TEEWINOT TECHNOLOGIES LIMITED
To: TUATARA CAPITAL FUND I, L.P.; TUATARA CAPITAL PARALLEL FUND I, L.P.
Reel/Frame 058194/0474 →
SECURITY INTEREST Recorded Nov 22, 2021
From: TEEWINOT TECHNOLOGIES LIMITED
To: TUATARA CAPITAL FUND I, L.P.; TUATARA CAPITAL PARALLEL FUND I, L.P.
Reel/Frame 058180/0377 →
SECURITY INTEREST Recorded Nov 22, 2021
From: TEEWINOT LIFE SCIENCES CORPORATION; TEEWINOT TECHNOLOGIES LIMITED
To: TUATARA CAPITAL FUND I, L.P.; TUATARA CAPITAL PARALLEL FUND I, L.P.
Reel/Frame 058182/0033 →
SECURITY INTEREST Recorded Aug 24, 2020
From: TEEWINOT TECHNOLOGIES, LTD.
To: TUATARA CAPITAL FUND I, L.P.
Reel/Frame 053582/0897 →
CHANGE OF NAME Recorded Dec 8, 2017
From: FULL SPECTRUM LABORATORIES LIMITED
To: TEEWINOT TECHNOLOGIES LIMITED
Reel/Frame 044804/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2016
From: WINNICKI, ROBERT; DONSKY, MARC
To: FULL SPECTRUM LABORATORIES LIMITED
Reel/Frame 040083/0476 →
Continuity (3)
Continuation PCTUS2014018944 · Feb 27, 2014
Provisional Application 61770766 · Feb 28, 2013
Related Publication 20150361469A1 · Dec 17, 2015